摘要
Excessive acute inflammatory response in coronavirus-induced disease 2019(COVID-19)patients results in multiple organ injury,especially acute respiratory distress syndrome(ARDS),contributing to a high mortality of the disease[1,2].More evidence showed that corticosteroid,an immunomodulatory agent,reduces both the need of invasive mechanical ventilation and lowers the mortality of severe COVID-19 patients.However,its optimal dose and therapeutic duration is still ambiguous.The RECOVERY trial revealed that using corticosteroid up to 10 days reduced the mortality of hospitalized COVID-19 patients[3]and a finding also upheld by a meta-analysis by Cano et al.[4].To the best of our knowledge,currently,there is no study evaluating disease progression after discontinuation of corticosteroid treatment in COVID-19 patients with ARDS.
